Browsing Tag
rexlemestrocel-L
4 posts
Mesoblast revenue jumps sevenfold to $120m as Ryoncil turns cell therapy into a commercial business
Mesoblast generated $120.3 million of FY26 revenue, including $115.2 million from Ryoncil, while narrowing its loss 44% and advancing adult GVHD, Duchenne, back pain and heart-failure programmes.
Mesoblast completes 350-patient Phase 3 treatment as mid-2027 back pain readout becomes next valuation test
Mesoblast has completed treatment of 350 Phase 3 back pain patients, putting rexlemestrocel-L on course for a pivotal mid-2027 efficacy readout.
Mesoblast (ASX: MSB; Nasdaq: MESO) CEO invests A$2.73m as Ryoncil growth shifts focus to execution
Mesoblast Chief Executive Silviu Itescu has paid A$2.73 million to increase his ownership, adding an alignment signal as Ryoncil sales and late-stage programs reshape the company.
Mesoblast (ASX: MSB) clears key treatment milestone ahead of mid-2027 back pain trial readout
Mesoblast has treated at least 300 patients in MSB-DR004, starting the final 12-month clock towards a mid-2027 readout and potential United States filing. The milestone strengthens execution visibility, but it does not provide new efficacy data.